治疗B细胞疾病可改善单克隆丙种球蛋白病相关C3肾小球病患者的肾脏结局
该研究从法国国家C3G数据库中提取50例单克隆免疫球蛋白(MIg)相关且活检证实的C3肾小球病(C3G)成人患者,回顾性比较接受与未接受针对B细胞克隆的化疗者的肾脏结局。化疗后获血液学缓解者肾脏缓解率更高(P=.0001),中位肾脏生存更优(HR 0.22,95%CI 0.05-0.92,P=.009)。作者认为针对B细胞克隆的化疗可能是MIg相关C3G的有效策略。
要点
- 50例MIg相关C3G患者中,化疗后获血液学缓解者肾脏缓解率更高(P=.0001)。
- 化疗后获血液学缓解者中位肾脏生存优于保守/免疫抑制治疗者(HR 0.22,95%CI 0.05-0.92,P=.009)。
- 诊断时肾脏病严重:肾病范围蛋白尿20/46(43%),慢性肾脏病3期及以上42/49(86%)。
核心结论
- 作者认为,针对B细胞克隆的化疗可能是MIg相关C3G的有效策略,因为快速获得血液学缓解似乎可改善肾脏生存。
研究设计与样本
- 回顾性研究,从法国国家C3G数据库中提取50例MIg相关且活检证实的C3G成人患者,比较接受与未接受针对B细胞克隆的化疗者的肾脏结局。
主要发现
- 诊断时肾病范围蛋白尿20/46(43%),慢性肾脏病3期及以上42/49(86%)。
- 单克隆丙种球蛋白病为IgG型47例(94%);血液学诊断:肾脏意义单克隆丙种球蛋白病30例(60%),多发性骨髓瘤17例(34%),慢性淋巴细胞白血病3例(6%)。
- 补体检查:C3水平降低22/50(43%),可溶性C5b-9水平升高27/34(79%)。
- 29例接受化疗(其中22例含硼替佐米),8例接受各种免疫抑制药物,13例仅接受对症治疗。
- 化疗后获血液学缓解者肾脏缓解率高于接受保守/免疫抑制治疗者(P=.0001)。
临床怎么用
- 作者认为,针对B细胞克隆的化疗可能是MIg相关C3G的有效策略,快速获得血液学缓解似乎可改善肾脏生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The high frequency of monoclonal gammopathy in adult patients with C3 glomerulopathy (C3G) emphasizes the role of monoclonal immunoglobulin (MIg) in the occurrence of renal disease and raises the issue of the therapeutic management. The aim of the study was to evaluate the effect of chemotherapy in a large cohort of patients with MIg-associated C3G. Fifty adult patients with MIg and biopsy-proven C3G were extracted from the French national database of C3G. We retrospectively compared renal outcomes in patients who either received or did not receive chemotherapy targeting the underlying B-cell clone. At diagnosis, renal disease was severe, with nephrotic-range proteinuria in 20/46 (43%) patients and chronic kidney disease stage 3 or above in 42/49 (86%) patients. Monoclonal gammopathy was of IgG type in 47 (94%) patients. Hematological diagnosis was monoclonal gammopathy of renal significance in 30 (60%), multiple myeloma in 17 (34%), and chronic lymphocytic leukemia in 3 (6%) patients. Complement studies showed low C3 level in 22/50 (43%) and elevated soluble C5b-9 level in 27/34 (79%) patients. Twenty-nine patients received chemotherapy (including bortezomib in 22), whereas 8 and 13 patients received various immunosuppressive drugs or symptomatic measures alone, respectively. Patients who achieved hematological response after chemotherapy had higher renal response rates (P = .0001) and median renal survival (hazard ratio, 0.22; 95% confidence interval, 0.05-0.92; P = .009) than those receiving conservative/immunosuppressive therapy. In conclusion, our results suggest that chemotherapy adapted to the B-cell clone may constitute an efficient strategy for C3G in the setting of MIg, as rapid achievement of hematological response appears to result in improved renal survival.
引用
- Chauvet S, Frémeaux-Bacchi V, Petitprez F, et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood. 2017. PMID: 28069603. doi:10.1182/blood-2016-08-737163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。